Prime Medicine (NASDAQ:PRME) Sets New 12-Month High – What’s Next?

Shares of Prime Medicine, Inc. (NASDAQ:PRME) reached a new 52-week high during trading on Tuesday . The stock traded as high as $6.94 and last traded at $6.08, with a volume of 4399761 shares traded. The stock had previously closed at $6.32.

Analysts Set New Price Targets

Several research firms have recently commented on PRME. Weiss Ratings restated a “sell (e+)” rating on shares of Prime Medicine in a report on Saturday, September 27th. Wall Street Zen cut Prime Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, September 2nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Prime Medicine Stock Performance

The firm has a market cap of $818.19 million, a price-to-earnings ratio of -3.90 and a beta of 2.65.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.